To study of renal adverse effects of Tenofovir in HIV infected children on ART
Phase 3
- Conditions
- Health Condition 1: B20- Human immunodeficiency virus [HIV]disease
- Registration Number
- CTRI/2022/09/045278
- Lead Sponsor
- Moti Lal Nehru Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.All HIV infected children from age 10 years or weight more than 30 kg to 21 years of age receiving Tenofovir containing ART for at least 6 months
2.eGFR more than 60 ml/min/m2
3.Individuals whose base line parameters available before starting ART treatment
Exclusion Criteria
1.History of Hypertension, Diabetes Mellitus, Congenital Heart disease, Chronic liver failure, Cardio Vascular Disease, Nephrotic syndrome.
2.Hepatitis B and C infection.
3.Transfer of care to other medical care facilities
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Changes of eGFR from base line <br/ ><br>2.Changes of serum creatinine from base line <br/ ><br>3.Changes in creatinine clearance from base lineTimepoint: 3 months
- Secondary Outcome Measures
Name Time Method 1.Changes of CD4 count from base line <br/ ><br>2.Changes of Serum phosphate during treatment <br/ ><br>3.Proteinuria during treatmentTimepoint: 3 months